CRBP
Corbus Pharmaceuticals Holdings (CRBP)
$
21About Corbus Pharmaceuticals Holdings (CRBP)
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Details
Daily high
$8.78
Daily low
$8.15
Price at open
$8.70
52 Week High
$61.90
52 Week Low
$8.01
Market cap
100.0M
Dividend yield
0.00%
Volume
250,937
Avg. volume
303,455
P/E ratio
-1.75
Corbus Pharmaceuticals Holdings News
Details
Daily high
$8.78
Daily low
$8.15
Price at open
$8.70
52 Week High
$61.90
52 Week Low
$8.01
Market cap
100.0M
Dividend yield
0.00%
Volume
250,937
Avg. volume
303,455
P/E ratio
-1.75